Drug-coated balloon (DCB) provides a new treatment strategy for peripheral artery diseases (PAD) and its effectiveness has been tested in several controlled studies in different countries, most of which focused on its use in femoropopliteal leisons. Compared with uncoated balloon, DCB can reduce late lumen loss and restenosis of femoropopliteal TASC-A/B lesions at 6 months and even 1 year after operation and decrease the re-intervention rate, but there is a lack of its mid- and long-term follow-up results as well as its efficacy for TASC-C/D lesions. Studies on using DCB in treatment of infra-popliteal diseases are relatively scarce, in which even more unfortunately, the results are not consistent with each other in terms of comparison between DCB and uncoated balloon. Thus, more high-quality well-controlled studies are urgently needed to answer these questions.